Novozymes B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novozymes AS (NSISb)
Novozymes AS stock price live, this page displays CSE NSISb stock exchange data. View the NSISb premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novozymes AS real time stock price chart below.
What Is the Novozymes AS Stock Price Today?
The Novozymes AS stock price today is 375.5.
What Is the Stock Symbol for Novozymes AS?
The stock symbol for Novozymes AS is "NSISb."
What Stock Exchange Does Novozymes AS Trade On?
Novozymes AS is listed and trades on the Copenhagen stock exchange.
Is Novozymes AS a Good Stock to Buy?
Determining whether Novozymes AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NSISb quote. (ISIN: DK0060336014)
What Is the Novozymes AS Stock Price Today?
The Novozymes AS stock price today is 375.5.
What Is the Stock Symbol for Novozymes AS?
The stock symbol for Novozymes AS is "NSISb."
What Stock Exchange Does Novozymes AS Trade On?
Novozymes AS is listed and trades on the Copenhagen stock exchange.
Is Novozymes AS a Good Stock to Buy?
Determining whether Novozymes AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NSISb quote. (ISIN: DK0060336014)
375.5
+3.5(+0.94%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
366.3
375.5
52 wk Range
366.1
489.4
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
366.3375.5
52 wk Range
366.1489.4
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.73%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.73%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NSISb Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
457.5
Upside
+21.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Novozymes B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novozymes B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Novozymes B receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novozymes B receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Novozymes AS Company Profile
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women’s, children’s cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it also provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
Compare NSISb to Peers and Sector
Metrics to compare | NSISb | Sector Sector - Average of metrics from a broad group of related Basic Materials sector companies | Relationship RelationshipNSISbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 42.8x | 18.1x | 2.3x | |
PEG Ratio | 0.28 | 0.06 | 0.00 | |
Price/Book | 2.2x | 1.5x | 1.6x | |
Price / LTM Sales | 5.6x | 1.4x | 1.4x | |
Upside (Analyst Target) | 25.2% | 2.6% | 15.7% | |
Fair Value Upside | Unlock | 7.0% | −3.7% | Unlock |
Analyst Ratings
11 Buy
5 Hold
2 Sell
Ratings:
18 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 457.5
(+21.84% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.30 / --
Revenue / Forecast
1.06B / 8.205B
People Also Watch
FAQ
What Is the Novozymes AS (NSISb) Stock Price Today?
The Novozymes AS stock price today is 375.5 DKK.
What Stock Exchange Does Novozymes AS Trade On?
Novozymes AS is listed and trades on the Copenhagen Stock Exchange.
What Is the Stock Symbol for Novozymes AS?
The stock symbol for Novozymes AS is "NSISb."
Does Novozymes AS Pay Dividends? What’s The Current Dividend Yield?
The Novozymes AS dividend yield is 1.73%.
What Is the Novozymes AS Market Cap?
As of today, Novozymes AS market cap is 174.85B DKK.
What Is Novozymes AS's Earnings Per Share (TTM)?
The Novozymes AS EPS (TTM) is 1.9.
From a Technical Analysis Perspective, Is NSISb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Novozymes AS Stock Split?
Novozymes AS has split 1 times.
How Many Employees Does Novozymes AS Have?
Novozymes AS has 10582 employees.
What is the current trading status of Novozymes AS (NSISb)?
As of Feb 28, 2026, Novozymes AS (NSISb) is trading at a price of 375.5 DKK, with a previous close of 372.0 DKK. The stock has fluctuated within a day range of 366.3 DKK to 375.5 DKK, while its 52-week range spans from 366.1 DKK to 489.4 DKK.
What Is Novozymes AS (NSISb) Price Target According to Analysts?
The average 12-month price target for Novozymes AS is 457.5 DKK, with a high estimate of 560 DKK and a low estimate of 362 DKK. 11 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +21.84% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.